Skip to main content

Posts tagged with "Cardiovascular Disease"

  • Cardiovascular Disease

    The Genomics Revolution Shows Up Late, But Shows Up

    Robert Plenge has an excellent overview of the PCSK9 story up on his site; I recommend it. His take may sound different from mine at first, but I think we’re actually in agreement on a lot of important points. I said that “PCSK9 is about as compelling a story as we’re likely to see in… Read More
  • Cardiovascular Disease

    What PCSK9 Is Telling Us About Drug Discovery

    Friday’s news about the real-world effects of PCSK9 drugs continue to reverberate. It’s worth going into the topic again, but from a wider view of genomics-driven medicine, because this is currently one of the biggest strategies for drug discovery in the industry. The reasoning behind this is pretty compelling. If you comb through the h… Read More
  • Business and Markets

    PCSK9: Real World Data Arrives, Unfortunately

    So, PCSK9. A wonderful story of genetics-based drug discovery, and a huge commercial opportunity. People with loss-of-function PCSK9 genes have very low LDL cholesterol, with no other ill effects, and people with gain-of-function mutations have chronically high cholesterol. That’s about as good as the validation gets, so a number of drug co… Read More
  • Business and Markets

    Amgen Will See You In Court – Again

    If they ever get around to making movies about drug discovery and development, perhaps someone will take on PCSK9. It has a neat origin in mutated humans, a race to the clinic, big money and big hopes, dramatic uncertainty (will it actually give better cardiovascular outcomes? Stay tuned!), and now it has courtroom scenes, too. Read More
  • Alzheimer's Disease

    Simple, Right?

    So, name a class of prescription drugs that lots of people have been taking daily over a period of decades: how about statins? From a distance, the story is completely understandable: statins inhibit the enzyme HMG-CoA reductase, which shuts down a key step in cholesterol biosynthesis. That lowers the amount of cholesterol in the body… Read More
  • Cardiovascular Disease

    The Long Saga of Apo-A1 Milano

    It’s been six years since I titled a post “Remember Apo-A1 Milano?” If you go back even further, I wrote about the topic on this blog back in 2003 (!); scroll down to the November 11 post on that page. You can see from that one that the saga goes well back into the 1990s, but… Read More
  • Biological News

    Is Selective Ribosome Stalling Possible? Apparently So

    PCSK9 is a drug target that’s famous in several directions. If you’re interesting in human genetics, it’s famous as an example of a “human knockout” – people with nonfunctional PCSK9, and there are a handful, have extraordinarily low levels of LDL, a finding that immediately got drug companies interested in findi… Read More
  • Cardiovascular Disease

    Once More Into the CETP, Friends

    So folks, let’s raise a bunch of money and pile back into CETP! You know, that great cardiovascular target that has been an absolute vale of tears for every big drug company that’s tried to develop it? What do you say? Interestingly enough, someone is doing just that. I wrote last year about DalCor, a Montreal-based… Read More
  • Cardiovascular Disease

    From the Far Corner of the Basement

    To go along with that recent CETP trial news, here’s another one for the “We don’t know much about human lipid handing” file. A dietary study originally done back in the 1960s and 1970s has been (almost literally) resurrected, with data pulled out of yellowing stacks of paper, old cardboard boxes, and ancient-format computer… Read More
  • Cardiovascular Disease

    CETP Finally Heads to the Trash Heap?

    The tale of CETP (cholesteryl ester transfer protein) as a drug target has been long, and convoluted, and expensive, and horrendously disappointing. Pfizer failed, Roche failed, several other companies like BMS who didn’t even get that far failed, and last fall Lilly’s entry failed, too (that link has links to several past blog posts he… Read More